Artwork

Content provided by Audioboom and MJH Life Sciences. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Audioboom and MJH Life Sciences or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Advancing Retinal Disease Treatment – The Next Generation of Anti-VEGF Therapies

31:39
 
Share
 

Manage episode 476499458 series 3310604
Content provided by Audioboom and MJH Life Sciences. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Audioboom and MJH Life Sciences or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
Ehsan Rahimy, MD; David G. Miller, MD; and Esther Kim, MD, discuss how achieving retinal drying through anti-VEGF therapies remains a critical marker of treatment success in retinal diseases such as age-related macular degeneration and diabetic macular edema while highlighting the benefits of newer agents such as aflibercept 8 mg and faricimab for providing better durability and sustained disease control with reduced treatment burden.
  continue reading

76 episodes

Artwork
iconShare
 
Manage episode 476499458 series 3310604
Content provided by Audioboom and MJH Life Sciences. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Audioboom and MJH Life Sciences or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
Ehsan Rahimy, MD; David G. Miller, MD; and Esther Kim, MD, discuss how achieving retinal drying through anti-VEGF therapies remains a critical marker of treatment success in retinal diseases such as age-related macular degeneration and diabetic macular edema while highlighting the benefits of newer agents such as aflibercept 8 mg and faricimab for providing better durability and sustained disease control with reduced treatment burden.
  continue reading

76 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide

Listen to this show while you explore
Play